Status: Recruiting
Evaluation of Treatment Efficacy According to Risk Group in Relapsed Childhood Acute Lymphoblastic Leukemia
This study is open-label, multi-center, prospective study, which targets childhood patients with relapsed acute lymphostatic leukemia including bone marrow recurrence. Aim of this study is to investigate the outcome of NGS MRD based risk stratified treatment for relapsed acute lymphoblastic leukemia in children and adolescents.
Participants needed: 90
Trial details
Phase: Phase 2Age: 1-22Biological sex: AllType: InterventionalSponsor: Ho Joon ImUpdated: Jun 6, 2025Locations: 7
Eligibility criteria
Patients <= 1 year and >22 years of age at the time of relapse will be eligible [+12]
Patients with Burkitt leukemia/lymphoma or mature B-cell leukemia [+12]